ESMO 2024: Targeting the Treatment Challenges of Small Cell Lung Cancer - Episode 3
Durvalumab in LS-SCLC: Exploring Phase 3 ADRIATIC Trial Outcomes and Implications
Panelists discuss how the interim results from the phase 3 ADRIATIC trial demonstrate significant overall survival and progression-free survival benefits for patients with limited-stage small cell lung cancer following concurrent chemoradiotherapy, highlighting the potential clinical relevance of durvalumab in improving life expectancy and its mechanisms of synergy within the tumor microenvironment.
Video content above is prompted by the following:
Dr Leal: Please discuss the interim results from the phase 3 ADRIATIC trial, which evaluated durvalumab in patients with limited-stage small cell lung cancer (LS-SCLC) who did not experience disease progression following concurrent chemoradiotherapy (cCRT) vs placebo after cCRT.
- Spigel D et al. Plenary Session 2024 ASCO Annual Meeting. LBA5; Spigel DR et al. J Clin Oncol. 2024;42(17 suppl):abstract LBA5. https://ascopubs.org/doi/10.1200/JCO.2024.42.17_suppl.LBA5
Dr Sen: How might the statistically significant overall survival and progression-free survival outcomes reported in ADRIATICtranslate into a clinically relevant improvement in life expectancy for your patients with LS-SCLC that has not progressed after cCRT?
- What are the mechanisms by which durvalumab synergizes with cCRT within the tumor microenvironment?
Related Content:
